Ketabon Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Joint Venture

  • Financing Rounds
  • 1

Ketabon General Information

Description

Operator of a contract research organization based in Munich, Germany. The company focuses on developing an oral prolonged-release (PR) formulation of ketamine for treatment-resistant depression (TRD) without dissociative side effects, helping healthcare providers to improve the risk profile and patient convenience, by eliminating dissociative side effects compared to the currently applied intravenous and intranasal therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Wilhelm-Wagenfeld Straße 20
  • 80807 Munich
  • Germany
Primary Industry
BPO/Outsource Services
Other Industries
Drug Discovery
Pharmaceuticals
Corporate Office
  • Wilhelm-Wagenfeld Straße 20
  • 80807 Munich
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ketabon Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ketabon‘s full profile, request access.

Request a free trial

Ketabon Patents

  • 21

    Total Documents Applications and Grants

  • Total Patents Families

  • 16

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Ketabon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3641742-A2 Hydroxynorketamine for the use in the treatment of depression Active 23-Jun-2017
EP-3641742-B1 Hydroxynorketamine for the use in the treatment of depression Active 23-Jun-2017
EP-4748442-A2 Hydroxynorketamine for the use in the treatment of depression Pending 23-Jun-2017
EP-4748442-A3 Hydroxynorketamine for the use in the treatment of depression Pending 23-Jun-2017
US-11723883-B2 Hydroxynorketamine for the use in the treatment of depression Active 23-Jun-2017 A61K31/135
To view Ketabon’s complete patent history, request access »

Ketabon Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ketabon‘s full profile, request access.

Request a free trial

Ketabon FAQs

  • When was Ketabon founded?

    Ketabon was founded in 2017.

  • Where is Ketabon headquartered?

    Ketabon is headquartered in Munich, Germany.

  • What industry is Ketabon in?

    Ketabon’s primary industry is BPO/Outsource Services.

  • Is Ketabon a private or public company?

    Ketabon is a Private company.

  • What is Ketabon’s current revenue?

    The current revenue for Ketabon is .

  • Who are Ketabon’s investors?

    Develco Pharma and HMNC Brain Health have invested in Ketabon.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process